Effect of bare metal stenting on angiographic and clinical outcomes in diabetic and nondiabetic patients undergoing percutaneous coronary intervention of nonacute occluded coronary arteries: A report from the Total Occlusion Study of Canada (TOSCA)

Catheterization and Cardiovascular Interventions

Volumn 66, Issue 2, 2005, Pages 178-184

  Yee, Kok Meng ^a   Buller, Christopher E ^b   Catellier, Diane ^c   Cohen, Eric A ^d   Carere, Ronald C ^e   Anderson, Todd ^f   Berger, Peter ^g   Burton, Jeffrey R ^h   Barbeau, Gerald ⁱ   Teo, Koon K ^j   Dzavik, Vladimir ^a,k  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e ST PAUL S HOSPITAL   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

ⁱ LAVAL UNIVERSITY   (Canada)

^j MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^k TORONTO GENERAL HOSPITAL   (Canada)

more..

Author keywords

Angioplasty; Diabetes; Stents; Total occlusion

Indexed keywords

METAL;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC ANGIOPATHY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; TREATMENT OUTCOME;

ANGIOPLASTY, BALLOON; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CANADA; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; FEMALE; HUMANS; MALE; METALS; MIDDLE AGED; PROSPECTIVE STUDIES; STENTS; TREATMENT OUTCOME;

EID: 26644459500     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20410     Document Type: Article

References (35)

1. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818-1825.
2. BARI investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 1997;96:1761-1769.
3. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-1146.
4. Van Belle E, Ketelers R, Bauters C, Perie M, Abolmaali K, Richard F, Lablanche JM, McFadden EP, Bertrand ME. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 2001;103:1218-1224.
5. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32:1866-1873.
6. Stein B, Weintraub WS, Gebhart SP, Cohen-Bernstein CL, Grosswald R, Liberman HA, Douglas JS Jr, Morris DC, King SB III. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979-89.
7. Van Belle E, Bauters C, Hubert E, Bodart JC, Abolmaali K, Meurice T, McFadden EP, Lablanche JM, Bertrand ME. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997;96:1454-1460.
8. Carrozza JP Jr, Kuntz RE, Fishman RF, Bairn DS. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993;118:344-349.
9. Buller CE, Dzavik V, Carere RG, Mancini GB, Barbeau G, Lazzam C, Anderson TJ, Knudtson ML, Marquis JF, Suzuki T, et al. Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). Circulation 1999;100:236-242.
10. Dzavik V, Carere RG, Teo KK, Knudtson ML, Marquis JF, Buller CE. An open design, multicentre, randomized trial of percutaneous transluminal coronary angioplasty versus stenting, with a heparin-coated stent, of totally occluded coronary arteries: rationale, trial design and baseline patient characteristics: Total Occlusion Study of Canada (TOSCA) investigators. Can J Cardiol 1998;14:825-832.
11. Ishizaka N, Issiki T, Saeki F, Ishizaka Y, Ikari Y, Abe J, Soumitsu Y, Hashimoto H, Masaki K, Yamaguchi T. Angiographic follow-up after successful percutaneous coronary angioplasty for chronic total coronary occlusion: experience in 110 consecutive patients. Am Heart J 1994;127:8-12.
12. Violaris AG, Melkert R, Serruys PW. Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions: a quantitative angiographic analysis. Circulation 1995;91:2140-2150.
13. Dzavik V, Beanlands DS, Davies RF, Leddy D, Marquis JF, Teo KK, Ruddy TD, Burton JR, Humen DP. Effects of late percutaneous transluminal coronary angioplasty of an occluded infarct-related coronary artery on left ventricular function in patients with a recent (< 6 weeks) Q-wave acute myocardial infarction (Total Occlusion Post-Myocardial Infarction Intervention Study [TOMIIS]: a pilot study). Am J Cardiol 1994;73:856-861.
14. Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini G. Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial-Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. J Am Coll Cardiol 1998;32:90-96.
15. Sirnes PA, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P, Brekke M, Mangschau A, Endresen K, Kjekshus J. Stenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. J Am Coll Cardiol 1996;28: 1444-1451.
16. Laskey WK, Selzer F, Vlachos HA, Johnston J, Jacobs A, King SB III, Holmes DR, Douglas J, Block P, Wilensky R, et al. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2002;90: f1062-1067.
17. Van Belle E, Perie M, Braune D, Chmait A, Meurice T, Abolmaali K, McFadden EP, Bauters C, Lablanche JM, Bertrand ME. Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 2002;40:410-417.
18. Kornowski R, Mintz GS, Kent KM, Pichard AD, Satler LF, Bucher TA, Hong MK, Popma JJ, Leon MB. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimai hyperplasia: a serial intravascular ultrasound study. Circulation 1997;95:1366-1369.
19. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-1774.
20. Davi G, Violi F, Catalano I, Giammarresi C, Putignano E, Nicolosi G, Barbagallo M, Notarbartolo A. Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina. Blood Coagul Fibrinolysis 1991;2:41-45.
21. Ganda OP, Arkin CF. Hyperfibrinogenemia: an important risk factor for vascular complications in diabetes. Diabetes Care 1992;15:1245-1250.
22. Ceriello A, Taboga C, Giacomello R, Falleti E, De Stasio G, Motz E, Lizzio S, Gonano F, Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 1994;43:430-432.
23. Avellone G, Di Garbo V, Cordova R, Rotolo G, Abruzzese G, Raneli G, De Simone R, Bompiani GD. Blood coagulation and fibrinolysis in obese NIDDM patients. Diabetes Res 1994;25: 85-92.
24. Rosove MH. Diabetes mellitus, hemostatic hyperfunction, and glycemic control. Thromb Haemost 1995;73:165-166.
25. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001;24: 1476-1485.
26. Aso Y, Matsumoto S, Fujiwara Y, Tayama K, Inukai T, Takemura Y. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Metabolism 2002;51:471-476.
27. Barazzoni R, Kiwanuka E, Zanetti M, Cristini M, Vettore M, Tessari P. Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes 2003;52:1851-1856.
28. Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, et al. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients: insights from the RAVEL trial. Eur Heart J 2004;25:107-112.
29. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
30. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-1947.
31. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-195.
32. Pajunen P, Taskinen MR, Nieminen MS, Syvanne M. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol 2000;86:1080-1085.
33. Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation 1999;100:2477-2484.
34. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000; 35:922-928.
35. Jackevicius CA, Pinto R, Daly P, Mackie K, Dzavik V. Routine use of glycoprotein IIb/IIIa inhibitor therapy is associated with an improved in-hospital outcome after percutaneous coronary intervention: Insights from a large, prospective, single-centre registry. Can J Cardiol 2005;21:27-32.